Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics

Hepatocellular carcinoma (HCC) is a common malignancy in developing countries and its incidence is on the rise in the developing world. The epidemiology of this cancer is unique since its risk factors, including hepatitis C and B, have been clearly established. The current trends in the shifting incidence of HCC in different regions of the world can be explained partly by the changing prevalence of hepatitis. Early detection offers the only hope for curative treatment for patients with HCC, hence effective screening strategies for high-risk patients is of utmost importance. Liver transplantation and surgical resection remains the cornerstone of curative treatment. But major advances in locoregional therapies and molecular-targeted therapies for the treatment of advanced HCC have occurred recently. In this review, current trends in the worldwide epidemiology, surveillance, diagnosis, standard treatments, and the emerging therapies for HCC are discussed.

[1]  William M. Lee,et al.  Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. , 2011, Gastroenterology.

[2]  M. Makuuchi,et al.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. , 2008, Gastroenterology.

[3]  Xianglin L. Du,et al.  Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States , 2010, Hepatology.

[4]  R. Lencioni,et al.  A critical appraisal of the literature on local ablative therapies for hepatocellular carcinoma. , 2005, Clinics in liver disease.

[5]  G. Dore,et al.  Hepatitis B‐related hepatocellular carcinoma: epidemiological characteristics and disease burden , 2009, Journal of viral hepatitis.

[6]  H. El‐Serag,et al.  The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  Samir Gupta,et al.  Test Characteristics of -Fetoprotein for Detecting Hepatocellular Carcinoma in Patients with Hepatitis C , 2003, Annals of Internal Medicine.

[8]  R. Dhanasekaran,et al.  Impact of Transarterial Therapy in Hepatitis C-Related Hepatocellular Carcinoma on Long-term Outcomes After Liver Transplantation , 2012, American journal of clinical oncology.

[9]  Rocio Lopez,et al.  The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2010, Hepatology.

[10]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[11]  J. Bruix,et al.  Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. , 2007, Journal of hepatology.

[12]  I. Williams,et al.  Epidemiology of hepatitis C in the United States. , 1999, The American journal of medicine.

[13]  Teruaki Kimura,et al.  Hepatocellular carcinoma with nonalcoholic steatohepatitis , 2004, Journal of Gastroenterology.

[14]  M. Abecassis,et al.  Yttrium‐90 microspheres (TheraSphere®) treatment of unresectable hepatocellular carcinoma: Downstaging to resection, RFA and bridge to transplantation , 2006, Journal of surgical oncology.

[15]  D. Madoff,et al.  Preoperative portal vein embolization: an approach to improve the safety of major hepatic resection. , 2011, Seminars in roentgenology.

[16]  M. Yamaguchi,et al.  Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: A prospective study , 1988, Hepatology.

[17]  Ping Liang,et al.  Microwave Ablation of Hepatocellular Carcinoma , 2007, Oncology.

[18]  Jeong Min Lee,et al.  Diagnostic Accuracy of Multi-/Single-Detector Row CT and Contrast-Enhanced MRI in the Detection of Hepatocellular Carcinomas Meeting the Milan Criteria before Liver Transplantation , 2008, Intervirology.

[19]  K. Glaser,et al.  ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. , 2008, Journal of hepatology.

[20]  M. Hebbar,et al.  Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma , 2008, Cancer.

[21]  A. Benson,et al.  Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. , 2010, Gastroenterology.

[22]  H. Hussain,et al.  Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially‐enhancing liver mass , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[23]  Y. Kuo,et al.  Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  J. Bruix,et al.  Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma , 1992, Hepatology.

[25]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[26]  ndrea,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[27]  Chien-Jen Chen,et al.  Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Chien-Jen Chen,et al.  Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma , 2008, Journal of the National Cancer Institute.

[29]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[30]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.

[31]  M. Thomas,et al.  Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma , 2011, Clinical Cancer Research.

[32]  M. Pompili,et al.  Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre , 2005, Gut.

[33]  M. Kudo,et al.  Effect of vitamin K2 on the recurrence of hepatocellular carcinoma , 2011, Hepatology.

[34]  J. Bruix,et al.  Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.

[35]  J. Marrero,et al.  Alpha‐fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the american association for the study of liver diseases , 2011, Hepatology.

[36]  J. Marrero,et al.  Alpha-fetoprotein in early hepatocellular carcinoma. , 2010, Gastroenterology.

[37]  Ching-Lung Lai,et al.  Natural history of hepatitis-related hepatocellular carcinoma. , 2008, World journal of gastroenterology.

[38]  M. Sherman Serological surveillance for hepatocellular carcinoma: time to quit. , 2010, Journal of hepatology.

[39]  J. Dufour,et al.  Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. , 2010, The oncologist.

[40]  C. Georgiades,et al.  Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. , 2005, Journal of vascular and interventional radiology : JVIR.

[41]  M. Vivarelli,et al.  Liver Transplantation for Recurrent Hepatocellular Carcinoma on Cirrhosis After Liver Resection: University of Bologna Experience , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[42]  T. Liang,et al.  Pathogenesis of hepatitis C-associated hepatocellular carcinoma. , 2004, Gastroenterology.

[43]  Jeffrey S. Morris,et al.  Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  W. Su,et al.  Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  K. Tai,et al.  A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[46]  J. Bruix,et al.  High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: An indication for salvage liver transplantation , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[47]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[48]  A. Benson,et al.  Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[50]  M. Manos,et al.  Incidence of hepatocellular carcinoma among individuals with hepatitis B virus infection identified using an automated data algorithm , 2007, Journal of viral hepatitis.

[51]  J. Bruix,et al.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma , 2007, Hepatology.

[52]  Ding‐Shinn Chen,et al.  Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[53]  M. Ozaki,et al.  Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[54]  H. El‐Serag,et al.  Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.

[55]  A. Mangia,et al.  Sustained virological response to interferon‐α is associated with improved outcome in HCV‐related cirrhosis: A retrospective study , 2007, Hepatology.

[56]  A. Lim,et al.  Imaging of liver cancer. , 2009, World journal of gastroenterology.

[57]  V. Lee,et al.  Transplantation for hepatocellular carcinoma and cirrhosis: Sensitivity of magnetic resonance imaging , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[58]  T. López-Cuadrado,et al.  Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma , 2009, BMC gastroenterology.

[59]  Chien-Jen Chen,et al.  Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. , 2009, Journal of the National Cancer Institute.

[60]  G. Dusheiko,et al.  Management of hepatocellular carcinoma. , 1992, Journal of hepatology.

[61]  J. Buckels,et al.  Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis , 2008, Gut.

[62]  Jae Young Lee,et al.  The Value of Gadobenate Dimeglumine-Enhanced Delayed Phase MR Imaging for Characterization of Hepatocellular Nodules in the Cirrhotic Liver , 2008, Investigative radiology.

[63]  Jeffrey W. Clark,et al.  Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma , 2007, Cancer.

[64]  Katsuyoshi Ito Hepatocellular carcinoma: conventional MRI findings including gadolinium-enhanced dynamic imaging. , 2006, European journal of radiology.

[65]  Akihiro Matsumoto,et al.  Hepatocellular carcinoma: recent trends in Japan. , 2004, Gastroenterology.

[66]  William M. Lee,et al.  Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. , 2010, Gastroenterology.

[67]  William M. Lee,et al.  Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. , 2008, The New England journal of medicine.

[68]  H. Yoshizawa Hepatocellular Carcinoma Associated with Hepatitis C Virus Infection in Japan: Projection to Other Countries in the Foreseeable Future , 2002, Oncology.

[69]  Lu-Yu Hwang,et al.  Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus , 2002, Hepatology.

[70]  T. Davern,et al.  A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[71]  M. Sherman,et al.  Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis , 2001, Gut.

[72]  H. El‐Serag,et al.  Risk factors for the rising rates of primary liver cancer in the United States. , 2000, Archives of internal medicine.

[73]  C. Zheng,et al.  Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. , 2004, World journal of gastroenterology.

[74]  J. Meyerhardt,et al.  Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC). , 2010 .

[75]  A. Benson,et al.  Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. , 2011, Gastroenterology.

[76]  B. Rubinsky,et al.  Tissue Ablation with Irreversible Electroporation , 2005, Annals of Biomedical Engineering.

[77]  J. Bruix,et al.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.

[78]  P Boffetta,et al.  A meta‐analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma , 1998, International journal of cancer.

[79]  G. Krinsky,et al.  Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis: correlation of pretransplantation sonography and liver explant pathology in 200 patients. , 2002, AJR. American journal of roentgenology.

[80]  Mauro Salizzoni,et al.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. , 2002, Gastroenterology.

[81]  Samir Gupta,et al.  Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. , 2003, Annals of internal medicine.

[82]  Chien-Jen Chen,et al.  Hepatitis B virus DNA levels and outcomes in chronic hepatitis B , 2009, Hepatology.

[83]  K. Wakasa,et al.  Hepatocellular Carcinoma Arising from Nonalcoholic Steatohepatitis: Report of Two Cases , 2005, Surgery Today.

[84]  J. Bruix,et al.  Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation , 1999, Hepatology.

[85]  R. Finn,et al.  Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma , 2011, Clinical Cancer Research.

[86]  T. George,et al.  The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma , 2011, Alimentary pharmacology & therapeutics.

[87]  F. Izzo,et al.  Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation , 2011, Hepatology.

[88]  Y. Tajima,et al.  Actual therapeutic efficacy of pre-transplant treatment on hepatocellular carcinoma and its impact on survival after salvage living donor liver transplantation , 2009, Journal of Gastroenterology.

[89]  A. Lok,et al.  Does Antiviral Therapy Prevent Hepatocellular Carcinoma? , 2011, Antiviral therapy.

[90]  S. Altekruse,et al.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  L. Jeng,et al.  Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. , 2009, Journal of hepatology.

[92]  William M. Lee,et al.  Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. , 2009, Gastroenterology.

[93]  M. Taniai,et al.  Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2009, Journal of Gastroenterology.

[94]  A. Zhu,et al.  A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC). , 2010 .

[95]  P. Waldenberger,et al.  Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[96]  Chi-Lai Ho,et al.  11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[97]  G. Gores,et al.  Drop‐out rates of patients with hepatocellular cancer listed for liver transplantation: Outcome with chemoembolization , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[98]  John Wong,et al.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.

[99]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.

[100]  S. Breitenstein,et al.  “State of the Art” in Liver Resection and Living Donor Liver Transplantation: A Worldwide Survey of 100 Liver Centers , 2009, World Journal of Surgery.

[101]  K. Ashizawa,et al.  Complications associated with transcatheter arterial embolization for hepatic tumors. , 1998, Radiographics : a review publication of the Radiological Society of North America, Inc.

[102]  C. Margarit,et al.  Resection of hepatocellular carcinoma in patients with cirrhosis , 1996, The British journal of surgery.

[103]  R. Wiesner,et al.  Results of the first year of the new liver allocation plan , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[104]  J. Willatt,et al.  MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. , 2008, Radiology.

[105]  S. Porru,et al.  Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. , 2002, American journal of epidemiology.

[106]  V. Cogliano International Agency for Research on Cancer (IARC) , 2018, The Grants Register 2019.

[107]  Stephanie R Wilson,et al.  An algorithm for the diagnosis of focal liver masses using microbubble contrast-enhanced pulse-inversion sonography. , 2006, AJR. American journal of roentgenology.

[108]  M. Friedrich-Rust,et al.  Tumor-Specific Vascularization Pattern of Liver Metastasis, Hepatocellular Carcinoma, Hemangioma and Focal Nodular Hyperplasia in the Differential Diagnosis of 1349 Liver Lesions in Contrast-Enhanced Ultrasound (CEUS) , 2009, Ultraschall in der Medizin.

[109]  Michiie Sakamoto,et al.  Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia , 2009, Hepatology.

[110]  P. Philip,et al.  Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  H. Tsukuma,et al.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease. , 1993, The New England journal of medicine.

[112]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[113]  Chang-Min Kim,et al.  A Prospective Evaluation of 18F-FDG and 11C-Acetate PET/CT for Detection of Primary and Metastatic Hepatocellular Carcinoma , 2008, Journal of Nuclear Medicine.

[114]  J. Bruix,et al.  East meets the West—portal pressure predicts outcome of surgical resection for hepatocellular carcinoma , 2009, Nature Clinical Practice Gastroenterology &Hepatology.

[115]  J. Kaldor,et al.  Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. , 2006, Journal of hepatology.

[116]  Yong Hwan Jeon,et al.  Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. , 2009, AJR. American journal of roentgenology.

[117]  M. Kudo,et al.  Small hepatocellular carcinomas in chronic liver disease: detection with SPECT. , 1986, Radiology.

[118]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[119]  R. Lencioni Loco‐regional treatment of hepatocellular carcinoma , 2010, Hepatology.

[120]  D. Geller,et al.  Bridging Locoregional Therapy for Hepatocellular Carcinoma Prior to Liver Transplantation , 2008, Annals of Surgical Oncology.

[121]  D. Harnois,et al.  Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression , 2010 .

[122]  M. Ebara,et al.  Diagnosis of small hepatocellular carcinoma: correlation of MR imaging and tumor histologic studies. , 1986, Radiology.

[123]  K. McGlynn,et al.  The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An Update , 2003, Annals of Internal Medicine.

[124]  Wolfgang Sadee,et al.  A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas , 2009, Clinical Cancer Research.

[125]  Young Kon Kim,et al.  Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma. , 2006, AJR. American journal of roentgenology.

[126]  Carlo Bartolozzi,et al.  Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. , 2003, Radiology.

[127]  T. Vogl,et al.  Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study , 2009, CardioVascular and Interventional Radiology.

[128]  S. Pol,et al.  The impact of human immunodeficiency virus on viral hepatitis , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[129]  H. El‐Serag Hepatocellular carcinoma and hepatitis C in the United States , 2002, Hepatology.

[130]  Zhao-You Tang,et al.  Randomized controlled trial of screening for hepatocellular carcinoma , 2004, Journal of Cancer Research and Clinical Oncology.

[131]  J. Groopman,et al.  Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[132]  M. Zoli,et al.  Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience) , 2002, American Journal of Gastroenterology.

[133]  B. Sangro,et al.  Comparative study of four different spherical embolic particles in an animal model: a morphologic and histologic evaluation. , 2008, Journal of vascular and interventional radiology : JVIR.

[134]  Yun Yen,et al.  A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer , 2009, Cancer Chemotherapy and Pharmacology.

[135]  M. Feitelson Hepatitis B virus in hepatocarcinogenesis , 1999, Journal of cellular physiology.

[136]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[137]  J. Marrero,et al.  Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort , 2005, Hepatology.

[138]  A. Young,et al.  Needle-track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. , 2009, Gut.

[139]  R. Finn,et al.  An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[140]  D. Parkin,et al.  The global health burden of infection‐associated cancers in the year 2002 , 2006, International journal of cancer.

[141]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[142]  S. Fan,et al.  Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. , 2000, Annals of surgery.

[143]  G. Casazza,et al.  Accuracy of Ultrasonography, Spiral CT, Magnetic Resonance, and Alpha-Fetoprotein in Diagnosing Hepatocellular Carcinoma: A Systematic Review , 2006, The American Journal of Gastroenterology.

[144]  R. Groszmann,et al.  American association for the study of liver diseases , 1992 .

[145]  Michael Gregor,et al.  Contrast‐enhanced ultrasound with SonoVue: Differentiation between benign and malignant focal liver lesions in 317 patients , 2009, Journal of clinical ultrasound : JCU.

[146]  P. Chow,et al.  Gadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians , 2011, International journal of hepatology.

[147]  C. Hellerbrand,et al.  Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications , 2010, Gut.

[148]  Carmen Ayuso,et al.  MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: An explant correlation , 2003, Hepatology.

[149]  D. Harnois The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis , 2010 .

[150]  G. Abou-Alfa,et al.  Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. , 2010, JAMA.

[151]  E. Somers International Agency for Research on Cancer. , 1985, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[152]  O. Matsui,et al.  Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. , 1991, Radiology.

[153]  R. Poon,et al.  Prevention of recurrence after resection of hepatocellular carcinoma: A daunting challenge , 2011, Hepatology.

[154]  Chien-Jen Chen,et al.  Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. , 2010, Gastroenterology.

[155]  S. Larsson,et al.  Coffee consumption and risk of liver cancer: a meta-analysis. , 2007, Gastroenterology.

[156]  Ruey-min Lee,et al.  A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma. , 2016, Journal of Clinical Oncology.

[157]  Laura Crocetti,et al.  Clinical management of focal liver lesions: the key role of real-time contrast-enhanced US , 2007, European radiology.